- Home
- PIII vs MDAI Comparison
PIII vs MDAI Comparison
Compare PIII & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- MDAI
- Stock Information
- Founded
- PIII 2015
- MDAI 2013
- Country
- PIII United States
- MDAI United States
- Employees
- PIII N/A
- MDAI N/A
- Industry
- PIII Medical/Nursing Services
- MDAI Medical/Dental Instruments
- Sector
- PIII Health Care
- MDAI Health Care
- Exchange
- PIII Nasdaq
- MDAI Nasdaq
- Market Cap
- PIII 32.2M
- MDAI 28.3M
- IPO Year
- PIII N/A
- MDAI N/A
- Fundamental
- Price
- PIII $0.19
- MDAI $2.06
- Analyst Decision
- PIII Buy
- MDAI Strong Buy
- Analyst Count
- PIII 3
- MDAI 3
- Target Price
- PIII $2.38
- MDAI $4.50
- AVG Volume (30 Days)
- PIII 5.4M
- MDAI 1.8M
- Earning Date
- PIII 11-12-2024
- MDAI 11-06-2024
- Dividend Yield
- PIII N/A
- MDAI N/A
- EPS Growth
- PIII N/A
- MDAI N/A
- EPS
- PIII N/A
- MDAI N/A
- Revenue
- PIII $1,476,630,000.00
- MDAI $27,264,000.00
- Revenue This Year
- PIII $21.45
- MDAI $61.78
- Revenue Next Year
- PIII N/A
- MDAI N/A
- P/E Ratio
- PIII N/A
- MDAI N/A
- Revenue Growth
- PIII 25.38
- MDAI 44.52
- 52 Week Low
- PIII $0.18
- MDAI $0.82
- 52 Week High
- PIII $1.35
- MDAI $3.72
- Technical
- Relative Strength Index (RSI)
- PIII 39.59
- MDAI 47.72
- Support Level
- PIII $0.19
- MDAI $1.95
- Resistance Level
- PIII $0.29
- MDAI $2.24
- Average True Range (ATR)
- PIII 0.03
- MDAI 0.30
- MACD
- PIII -0.00
- MDAI -0.07
- Stochastic Oscillator
- PIII 4.30
- MDAI 11.54
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.